Audited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genpharmasec Limited reported audited standalone revenue of ₹13,134.94 Lakhs for FY2026, a massive jump from ₹3,296.07 Lakhs in FY2025 (approx. 298% YoY growth), driven partly by the acquisition of Derren Healthcare Private Limited (70% stake, effective July 2025) which became a subsidiary. Standalone PAT grew to ₹544.96 Lakhs from ₹280.04 Lakhs (approx. 95% YoY). The company reclassified equity shares worth Rs. 89.32 Lakhs from Inventories to Financial Investments (FVOCI) as a retrospective change in accounting policy. Statutory auditor Bilimoria Mehta & Co. issued an unmodified opinion for both standalone and consolidated results. On consolidation, one subsidiary (Derren) posted a net loss of ₹346.76 Lakhs and cash outflow of ₹108.27 Lakhs. Operating cash flow turned positive at ₹192.76 Lakhs vs negative ₹136.80 Lakhs in the prior year.
Strong standalone financial performance with multi-fold revenue and PAT growth is positive. However, auditors have flagged going concern uncertainty for two subsidiaries (Derren Healthcare and Clinigenome India), which have eroded net worth and current liabilities exceeding current assets, creating contingent risk for the Group.